From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction.

Medically reviewed by Katlein Franca, MD Guttate psoriasis causes small, round bumps. It's typically triggered by a Streptococcus (strep) bacteria infection. Guttate psoriasis most commonly affects ...

These data indicate that "prolonged [TNF inhibitor] treatment plays a protective role in PsA development in severe psoriasis patients," the researchers wrote. This is important, in that some previous ...

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

Researchers conducted a phase 3b randomized study of a cohort in the VISIBLE trial, which included 103 adults with skin of color and moderate-to-severe psoriasis (mean age, 44.1 years; 28.2% women ...

The efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis are currently being evaluated in the Phase 3 ONWARD clinical program, which consists of two parallel ...

Alumis Inc. completed patient enrollment in its Phase 3 trials for ESK-001, targeting moderate-to-severe plaque psoriasis. Quiver AI Summary. Alumis Inc. has announced the successful completion of ...

This multicenter, randomized, double-blind, placebo-controlled trial randomized (1:1:1:1) 145 Chinese patients with moderate to severe plaque psoriasis to receive AC-201 25mg BID, 50mg BID or ...

The efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis are currently being evaluated in the Phase 3 ONWARD clinical program, which consists of two parallel ...